http://files.e2ma.net/31451/assets/docs ... _teams.pdf
Dr. John Corboy, co-director of the Rocky Mountain MS Center at Anschutz Medical Campus
CCSVI: NMSS and the MS Society of Canada announce research funding recipients
With a continuing storm of attention, CCSVI is still the hottest topic in MS research. With many questions still to be answered, research on the investigational therapy is moving forward. In fact, on July 1st a slew of new CCSVI-specific studies will begin, each of which will be funded by the National MS Society (NMSS) or the MS Society of Canada.
In the last 6 months, the two organizations have been reviewing CCSVI-specific research proposals that they received after issuing a “request for proposals” in November 2009. NMSS' request went out to institutions and researchers in the U.S., and the MS Society’s to those in Canada. The proposals were reviewed by an international panel that was made up of specialists in the areas of radiology, vascular surgery and neurology.
Although the competition was tough, the proposals were narrowed down and 7 research initiatives in Canada and the U.S. were selected. The recipients will receive a combined $2.4 million over 2-years. The funding cycle begins July 1st, and recruitment for the studies will begin sometime shortly thereafter. To see a list of the 7 selected research projects, please click HERE.
It is important to note that none of the 7 studies are treatment studies, but rather will investigate the biological relationship between CCSVI and MS. First, researchers will focus on replicating the initial CCSVI study results presented by Dr. Paulo Zamboni of Italy; second, they will resolve questions surrounding how often CCSVI occurs in MS patients compared to non-affected controls; and third, assuming the presence of CCSVI and its link to MS are confirmed, these initial studies will help researchers understand how to proceed with treatment studies.
Only one upcoming study at the University of Buffalo will focus on CCSVI treatment by comparing the efficacy of percutaneous transluminal angioplasty (PTA) to a placebo treatment in 30 relapsing-remitting MS patients. Under the direction of Dr. Robert Zivadinov, the study will begin enrolling participants shortly.